|
1
|
Fabian ID, Onadim Z, Karaa E, Duncan C,
Chowdhury T, Scheimberg I, Ohnuma SI, Reddy MA and Sagoo MS: The
management of retinoblastoma. Oncogene. 37:1551–1560. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kivelä T: The epidemiological challenge of
the most frequent eye cancer: Retinoblastoma, an issue of birth and
death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shields CL, Lally SE, Leahey AM, Jabbour
PM, Caywood EH, Schwendeman R and Shields JA: Targeted
retinoblastoma management: When to use intravenous, intra-arterial,
periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol.
25:374–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chantada GL, Qaddoumi I, Canturk S, Khetan
V, Ma Z, Kimani K, Yeniad B, Sultan I, Sitorus RS, Tacyildiz N and
Abramson DH: Strategies to manage retinoblastoma in developing
countries. Pediatr Blood Cancer. 56:341–348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sengupta S, Pan U and Khetan V: Adult
onset retinoblastoma. Indian J Ophthalmol. 64:485–491. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jabbour P, Chalouhi N, Tjoumakaris S,
Gonzalez LF, Dumont AS, Chitale R, Rosenwasser R, Bianciotto CG and
Shields C: Pearls and pitfalls of intraarterial chemotherapy for
retinoblastoma. J Neurosurg Pediatr. 10:175–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaliki S, Shields CL, Rojanaporn D,
Al-Dahmash S, McLaughlin JP, Shields JA and Eagle RC Jr: High-risk
retinoblastoma based on international classification of
retinoblastoma: Analysis of 519 enucleated eyes. Ophthalmology.
120:997–1003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Canturk S, Qaddoumi I, Khetan V, Ma Z,
Furmanchuk A, Antoneli CB, Sultan I, Kebudi R, Sharma T,
Rodriguez-Galindo C, et al: Survival of retinoblastoma in
less-developed countries impact of socioeconomic and health-related
indicators. Br J Ophthalmol. 94:1432–1436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bracken CP, Scott HS and Goodall GJ: A
network-biology perspective of microRNA function and dysfunction in
cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang W and Luo YP: MicroRNAs in breast
cancer: Oncogene and tumor suppressors with clinical potential. J
Zhejiang Univ Sci B. 16:18–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu X and Li Z: The role of miRNAs in
cutaneous squamous cell carcinoma. J Cell Mol Med. 20:3–9. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gui F, Hong Z, You Z, Wu H and Zhang Y:
MiR-21 inhibitor suppressed the progression of retinoblastoma via
the modulation of PTEN/PI3K/AKT pathway. Cell Biol Int.
40:1294–1302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang LL, Hu HF and Feng YQ: Suppressive
effect of microRNA-143 in retinoblastoma. Int J Ophthalmol.
9:1584–1590. 2016.PubMed/NCBI
|
|
16
|
Yang L, Wei N, Wang L, Wang X and Liu QH:
miR-498 promotes cell proliferation and inhibits cell apoptosis in
retinoblastoma by directly targeting CCPG1. Childs Nerv Syst.
34:417–422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Zhu X, Zhu X, Wu Y, Liu Y, Yao B
and Huang Z: MiR-613 suppresses retinoblastoma cell proliferation,
invasion, and tumor formation by targeting E2F5. Tumour Biol.
39:10104283176916742017.PubMed/NCBI
|
|
18
|
Golabchi K, Soleimani-Jelodar R, Aghadoost
N, Momeni F, Moridikia A, Nahand JS, Masoudifar A, Razmjoo H and
Mirzaei H: MicroRNAs in retinoblastoma: Potential diagnostic and
therapeutic biomarkers. J Cell Physiol. 233:3016–3023. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mirakholi M, Mahmoudi T and Heidari M:
MicroRNAs horizon in retinoblastoma. Acta Med Iran. 51:823–829.
2013.PubMed/NCBI
|
|
20
|
Guan Y, Chen L, Bao Y, Pang C, Cui R, Li
G, Liu J and Wang Y: Downregulation of microRNA-504 is associated
with poor prognosis in high-grade glioma. Int J Clin Exp Pathol.
8:727–734. 2015.PubMed/NCBI
|
|
21
|
Kikkawa N, Kinoshita T, Nohata N, Hanazawa
T, Yamamoto N, Fukumoto I, Chiyomaru T, Enokida H, Nakagawa M,
Okamoto Y and Seki N: microRNA-504 inhibits cancer cell
proliferation via targeting CDK6 in hypopharyngeal squamous cell
carcinoma. Int J Oncol. 44:2085–2092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang MH, Lin BR, Chang CH, Chen ST, Lin
SK, Kuo MY, Jeng YM, Kuo ML and Chang CC: Connective tissue growth
factor modulates oral squamous cell carcinoma invasion by
activating a miR-504/FOXP1 signalling. Oncogene. 31:2401–2411.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang Y, Li B, Xu X, Shen L, Bai H, Gao F,
Zhang Z and Jonas JB: Lentivirus-mediated knockdown of astrocyte
elevated gene-1 inhibits growth and induces apoptosis through MAPK
pathways in human retinoblastoma cells. PLoS One. 11:e01487632016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu S, Zhang X, Hu C, Wang Y and Xu C:
miR-29a inhibits human retinoblastoma progression by targeting
STAT3. Oncol Rep. 39:739–746. 2018.PubMed/NCBI
|
|
26
|
Liang Y, Chen X and Liang Z: MicroRNA-320
regulates autophagy in retinoblastoma by targeting hypoxia
inducible factor-1α. Exp Ther Med. 14:2367–2372. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui R, Guan Y, Sun C, Chen L, Bao Y, Li G,
Qiu B, Meng X, Pang C and Wang Y: A tumor-suppressive microRNA,
miR-504, inhibits cell proliferation and promotes apoptosis by
targeting FOXP1 in human glioma. Cancer Lett. 374:1–11. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao L, Tang M, Hu Z, Yan B, Pi W, Li Z,
Zhang J, Zhang L, Jiang W, Li G, et al: miR-504 mediated
down-regulation of nuclear respiratory factor 1 leads to
radio-resistance in nasopharyngeal carcinoma. Oncotarget.
6:15995–16018. 2015.PubMed/NCBI
|
|
29
|
Soutto M, Chen Z, Saleh MA, Katsha A, Zhu
S, Zaika A, Belkhiri A and El-Rifai W: TFF1 activates p53 through
down-regulation of miR-504 in gastric cancer. Oncotarget.
5:5663–5673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li WF, Wang G, Zhao ZB and Liu CA: High
expression of metadherin correlates with malignant pathological
features and poor prognostic significance in papillary thyroid
carcinoma. Clin Endocrinol (Oxf). 83:572–580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Emdad L, Sarkar D, Lee SG, Su ZZ, Yoo BK,
Dash R, Yacoub A, Fuller CE, Shah K, Dent P, et al: Astrocyte
elevated gene-1: A novel target for human glioma therapy. Mol
Cancer Ther. 9:79–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gnosa S, Shen YM, Wang CJ, Zhang H,
Stratmann J, Arbman G and Sun XF: Expression of AEG-1 mRNA and
protein in colorectal cancer patients and colon cancer cell lines.
J Transl Med. 10:1092012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu R and Tian Y: Astrocyte elevated
gene-1 increases invasiveness of NSCLC through up-regulating MMP7.
Cell Physiol Biochem. 37:1187–1195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu JQ, Zhou Q, Zhu H, Zheng FY and Chen
ZW: Overexpression of astrocyte elevated gene-1 (AEG-1) in cervical
cancer and its correlation with angiogenesis. Asian Pac J Cancer
Prev. 16:2277–2281. 2015. View Article : Google Scholar : PubMed/NCBI
|
